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Abstract This retrospective study was designed to
evaluate the outcome of pregnancies in women diag-
nosed with systemic lupus erythematosus (SLE) fol-
lowed in a tertiary fetal–maternal center. Data were
collected from clinical charts between January 1993 and
December 2007, with a total of 136 pregnancies (107
patients). Mean maternal age was 29 years, with the
vast majority of patients being Caucasian. Most patients
were in remission 6 months prior to pregnancy (93%)
and the most frequently affected organs were the skin
and joints. Renal lupus accounted for 14% of all cases.
Twenty-nine percent of patients were positive for at
least one antiphospholid antibody (aPL) and nearly 50%
had positive SSa/SSb antibodies. All patients with
positive aPL received low-dosage aspirin and low-
molecular-weight heparin (LMWH). There were no
pregnancy complications in more than 50% of cases
and hypertensive disease and intrauterine growth restric-
tion were the most common adverse events. There were
125 live births, one neonatal death, eight miscarriages,
and three medical terminations of pregnancy. Preterm
delivery occurred in 25% of pregnancies. Our results are
probably the conjoined result of a multidisciplinary
approach together with a systematic management of
SLE pregnancies, with most patients keeping their prior
SLE medication combined with low-dosage aspirin and
LMWH in the presence of aPL.
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Introduction
Systemic lupus erythematosus (SLE) is a multisystemic
disease predominantly affecting women in their repro-
ductive years. It affects one in every 700 women with a
peak incidence at around age 30 [1]. As the treatment of
SLE improves, more women with this condition are able
to become pregnant and the pregnancy loss rate has fallen
from 43% in the 1960s to 17% by 2000 [2]. Women with
SLE have complicated pregnancies, with higher rates of
fetal demise, hypertensive disease, thromboembolism,
fetal growth restriction (FGR), premature delivery and
neonatal death. Many of these complications can be
attributed to SLE treatment more than to the disease itself.
Several factors are believed to influence the outcome of
pregnancy, namely lupus activity, antiphospholipid anti-
bodies, renal status, hypertension and medication compli-
cations [3–5].
Antiphospholipid antibodies (aPL) are associated with
arterial and venous thrombosis, pregnancy loss and throm-
bocytopenia although the presence of these antibodies per
se has not been conclusively shown to be causal in
thrombosis and miscarriage [6, 7]. These antibodies are
present in one third of patients with SLE (currently one
diagnostic criteria according to the American College of
Rheumatology), and its presence is associated with worse
pregnancy outcome in SLE patients [5].
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Between 1993 and 2007, 107 women diagnosed with SLE
(106 prior to pregnancy and one patient diagnosed during
pregnancy) were followed at our autoimmune pregnancy
clinic, accounting for 136 lupus pregnancies.
Pregnancies electively terminated for reasons other than
medical were excluded from the study.
Methods
Retrospective study based on clinical charts assessing
demographic, clinical, laboratory, therapeutic, pregnancy,
and neonatal data. All data were submitted to descriptive
summary statistical analysis.
Secondary antiphospholipid syndrome was diagnosed
according to the Sapporo criteria [8].
The following definitions were used:
Nullipara: a woman who has never completed a
pregnancy beyond an abortion
Multipara: a woman who has completed two or more
pregnancies to viability
Pregnancy loss is defined as any pregnancy that does not
result in a live infant beyond 28 days. A miscarriage is a
spontaneous pregnancy loss before 20 weeks gestation and
stillbirth is a pregnancy loss after 20 weeks gestation.
Neonatal death: death of a live-born infant within
28 days of birth
Preterm delivery: a birth which takes place after at least
20, but less than 37, completed weeks of gestation
related to last menstrual period (LMP)
Fetal growth restriction (FGR): fetal weight below the
tenth percentile for gestational age.
Oligohydramnios: amniotic fluid index <5
Hypertension was defined as a systolic blood pressure
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg.
Thrombocytopenia was defined as a platelet count below
150,000/mm3
Pregnancy management
Patients were regularly examined according to obstetric and
SLE evolution. At each visit, after vital signs assessment,
every patient was submitted to a dipstick urine test and, if
positive for proteinuria, to a 24-h urine collection for total
protein measurement.
Blood tests included standard obstetric evaluation
with special attention to renal, hepatic and coagulation
parameters. All patients were screened for the presence
of aPL (lupus anticoagulant, anticardiolipin antibodies,
beta-2-glycoprotein I).
Obstetric evaluation with standard sonographic eval-
uation plus additional uterine and umbilical Doppler
flow was performed at 22, 28, and 32 weeks gestation
and whenever indicated. Fetal echocardiogram was
performed at 24 weeks gestation in patients with SSa/
SSb-positive antibodies.
Patients were instructed to keep their SLE-specific
medication (corticosteroids, hydroxychloroquine, azatio-
prin, cyclosporine) throughout pregnancy.
All women presenting with positive aPL, even in the
absence of clinical criteria for secondary antiphospholi-
pid syndrome, received low-dosage aspirin and low-
molecular-weight heparin after confirmation of fetal
heart activity by fetal scan.
Results
Maternal
During the study period, there were 100,200 deliveries
in Dr. Alfredo da Costa Maternity, of which 136 were
lupus pregnancies followed in our clinic. Only one
diagnosis was made during pregnancy, with all the
others already studied and managed in rheumatology,
nephrology, and internal medicine clinics from other
centers before pregnancy.
Patients were mainly referred by other hospitals from the
National Health System (84%) and, in 5% of cases, from
private clinics; referral data were missing in 11% of cases.
Mean maternal age was 29 years and most women were
nulliparous (Table 1).
Seventy-eight percent of women first attended our clinic
during the first trimester (<14 weeks gestation) and 25%
had a pre-conceptional visit. Mean gestational age at first
visit was 11 weeks.
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The most frequent comorbid illness in women with SLE
was chronic hypertension (4% cases).
In terms of disease characteristics, articular and skin
involvement accounted for the majority of cases,
followed by kidney, blood, central nervous system, and
serosal manifestations (Table 2). A high proportion of
women were in remission for more than 6 months
previous to pregnancy (93%) and as for their immuno-
logic profile, antiphospholipid antibodies (lupus antico-
agulant, anticardiolipin antibodies, beta-2-glycoprotein I)
were positive (at least one) in 29% of women with
nearly 50% of patients testing positive for anti SSa/SSb
antibodies.
Eighty-six percent of patients received SLE-specific
medication (mainly corticosteroids, hydroxychloroquine,
and azatioprin); 4% discontinued medication on their own
initiative during pregnancy; the remaining were related to
cutaneous lupus without treatment.
Pregnancy outcome
Maternal
There were no complications in more than half the
pregnancies (52% of cases) (Table 3). Nineteen patients
developed hypertensive disease, with three cases of
HELLP syndrome (hemolysis, elevated liver enzymes,
low platelets). Lupus flares occurred in fivr patients during
pregnancy (four renal and one articular). The articular
lupus flare occurred after discontinuation of therapy and in
all but one case of renal flare, the patients were in
remission for more than 6 months; all renal lupus cases
kept their medication.
There were no cases of maternal death
Delivery
Ninety-four deliveries occurred after 37 weeks, with a
preterm delivery rate of 25% (Table 4). Mean gestational
age was 36.8 weeks (min—27 weeks; max—40 weeks).
Most patients had a vaginal delivery (55%) and cesarean
section was performed in 61 cases mainly for fetal distress.
Fetal
There were 125 deliveries (121 singleton and four twin
pregnancies), one neonatal death, eight miscarriages before
12 weeks of gestation, and three medical terminations of
pregnancy before 20 weeks of gestation. The latter were all
for severe oligohydramnios (two renal and one articular
lupus).
Fetal growth restriction occurred in 14% of cases with
no obvious relationship with SLE activity or the presence
of aPL.
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There were no cases of stillbirth.
The neonatal death was a baby delivered at 39 weeks by
cesarean section for fetal distress with an APGAR score of
0/2 at the first and fifth minute, respectively, that died on
the 13th day with the diagnosis of severe asphyxia and
grade 3 hypoxic–ischemic encephalopathy. Fetal weight at
birth was 3,648 g. The mother was a 36-year-old
nulliparous with cutaneous lupus with 4 years duration
and in remission for more than 6 months prior to
pregnancy. She was negative for aPL antibodies and was
medicated with prednisone 5 mg/day prior to pregnancy,
which was unchanged during gestation. She developed
gestational diabetes on the third trimester, managed with
diet only and had no other co-morbidities. There were no
post-partum complications, namely flares.
Newborns
Seventy-five percent of newborns had a birth weight above
2,500 g, with 20% low-weight babies (<2,500 g) and 5% of
very-low-weight babies (<1,500 g).
There were two cases of neonatal asphyxia.
There were no cases of neonatal lupus or congenital
heart block.
Discussion
Systemic lupus erythematosus <<<(SLE) is a complex
chronic inflammatory disease that affects multiple organ
systems and is clinically characterized by periods of remission
and relapse [9]. The disease predominantly affects women
and the incidence peaks between ages 15 and 45 years, i.e.,
the childbearing years, when the female-to-male ratio is
about 12:1.
Whether SLE activity increases during pregnancy has
been a matter of debate over the last years although recent
studies have found a two- to threefold increase in SLE
activity during pregnancy [4, 10–12]. Differentiation of
signs and symptoms of normal pregnancy from those of
exacerbations of lupus (e.g. chloasma vs. malar rash,
proteinuria secondary to preeclampsia vs. proteinuria due
to lupus nephritis) can be particularly difficult, which
clearly constitutes a bias when assessing reported incidence
and prevalence rates. On the other hand, in the past, many
patients used to stop all their therapy upon discovering that
they were pregnant which may have contributed to an
increased risk of flare in pregnancy [10, 11, 13].
When compared with other women, SLE patients are at
increased risk for maternal and fetal complications [14, 15].
According to the literature, one third of pregnancies will
result in a cesarean section, 33% will have preterm birth,
and more than 20% will be complicated by preeclampsia [3,
4, 12, 16]. Pregnancy outcome in SLE and the risks for
these complications relate to lupus activity, antiphospholi-
pid antibodies, renal status, hypertension, and medication
complications [4, 10, 13, 15].
The vast majority of our population was in remission
prior to pregnancy and kept their medication throughout the
gestation. The apparent low incidence of lupus flares in our
population might be, at least partially, attributed to these
aspects.
Antiphospholipid antibodies were present in 29% of
patients identical to most SLE series [6, 7]. All of these
received aspirin and heparin. This approach is still
controversial in the absence of clinical criteria for anti-
phospholipid syndrome [8]. From our experience, this
therapy is not associated with worse maternal or fetal
outcome namely bleeding disorders or osteoporosis
reported in the literature [17]. In our population, aPL
positivity was associated with more first-trimester miscar-
riages with no significant differences in maternal and
perinatal parameters such as medical complications, FGR,
gestational age at delivery, preterm delivery rate, cesarean
section rate, and APGAR score.
Renal lupus accounted for 28% of cases but was
responsible for 80% of the flares which highlights renal
lupus as a major risk factor for adverse events in pregnancy
[14, 15, 18].
Hypertension and FGR were the most common compli-
cations, as expected. There was no clear relation between
SLE activity or aPL and these events.
Our preterm delivery rate (25%) was similar to the
published data [3, 4].
Cesarean section was performed in 45% of patients, a
figure higher than the published data although the main
indications were related to fetal distress and not for
maternal indication. One possible reason for this is the
lower compliance of clinicians to signs of fetal distress in
SLE “risky” patients.
Long-term effects of lupus in the offspring of SLE
women are rare but include congenital heart block which
can ultimately lead to the implantation of a definite
pacemaker [19–23]. Positive SSa/SSbs are surrogates to
this complication and all SLE patients should be screened
for its presence. While most centers recommend a fetal
echocardiogram every 4 weeks after 16 weeks gestation,
our policy is to make an initial evaluation at 24 weeks
gestation, with no need for further investigation if normal.
Despite a high incidence of positive SSa/SSb patients
(nearly 50%), there were no cases of congenital heart block
in our series.
In conclusion, once considered a relative contra-
indication for pregnancy, SLE is no longer a reason for
women not to get pregnant assuring that “safety” measures
are taken and the expected course of pregnancy is fully
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explained to the patient, which is a major active participant
in the process. Given the potential complications and
morbidity, all pregnant women with SLE should be
considered high risk and managed by a multidisciplinary
team, ideally including a rheumatologist, an obstetrician
with experience in lupus, an internist and, if indicated, a
nephrologist [1].
Our autoimmune pregnancy clinic gathers the former
conditions, with experienced obstetricians, an internal
medicine specialist, and an excellent relationship with
the other specialties. The majority of pregnancies in
women with SLE in our series was successful and
although associated with higher rates of prematurity and
cesarean section than in normal subjects, these results
are globally positive.
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